Pfizer Inc.

PFE

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000078003

E

weakest fifth of 305 graded peers in healthcare

rank 293 of 305; percentile 96.1; sampling error 2.8 points; lower is stronger

A B C D E


E, the bear



Scoreboard


Profitability	D percentile 74.0
Solvency	E percentile 87.4
Growth and financing	C/D percentile 61.8
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $208.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	8 of 13
Graded from	filings received through Feb 26, 2026 268 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$27.43 2026-11-20; market equity $156.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

section. In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our products. In addition, our patented products may face generic or biosimilar competition before patent-based and/or regulatory exclusivity expires, including from "at-risk" launch (despite pending patent infringement litigation against the generic or biosimilar product) by a manufacturer of a generic or biosimilar version of one of our patented products.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 74.0						
Gross profitability	22.3%	32.8%		61.2	346	2025-12-31
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(1.9%)	(6.7%)	77.2	756	2025-12-31
Gross margin stability, five years	8.7 pts	2.8 pts	83.5	237	2025-12-31
Solvency, sleeve percentile 87.4					
Altman Z double-prime	not computable	0.31			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	1.16x	2.68x	87.4	781	2025-12-31
Growth and financing, sleeve percentile 61.8					
Revenue growth, three-year compound	(14.8%)	9.6%	87.0	400	2025-12-31
Free cash flow growth, three-year compound	(29.6%)	11.1%	95.7	94	2025-12-31
Reinvestment rate	not computable	33.9%			
one or more required annual facts are missing					
Asset growth, three years	1.8%	3.2%	48.0	663	2025-12-31
Net share issuance, one year	0.3%	1.6%	16.5	626	2026-02-19

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
288	Co-Diagnostics, Inc. (CODX)	94.4	E	dilution, short runway, fortress balance sheet
289	Fortress Biotech, Inc. (FBIO)	94.7	E	fortress balance sheet
290	Kyntra BIO, Inc. (KYNB)	95.1	E	short runway, distress
291	VivoSim Labs, Inc. (VIVS)	95.4	E	dilution, late filer
292	Biomerica Inc. (BMRA)	95.7	E	
293	Pfizer Inc. (PFE)	96.1	E	
294	Dare Bioscience, Inc. (DARE)	96.4	E	dilution
295	Longeveron Inc. (LGVN)	96.7	E	short runway
296	ALX Oncology Holdings Inc. (ALXO)	97.0	E	dilution, degenerate inputs, fortress balance sheet
297	Clene Inc. (CLNN)	97.4	E	dilution, distress
298	Nektar Therapeutics (NKTR)	97.7	E	dilution, short runway

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	23.8%	(1.7%)	65
Distance from 52-week high	(11.0%)	(33.0%)	77
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	5.8%	0.6%	82

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.57	0.29	70
Sales to price	0.40	0.38	53
Composite equity issuance, five years	(27.6%)	13.5%	5
Relative strength against the sector, log excess return	0.04	(0.19)	65
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.8B
Operating cash flow, four quarters	$14.2B
Months of runway	not finite
Days since last periodic filing	18 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$887.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$62.6B	2025-12-31	2026-02-26	10-K	26-000026
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$16.1B	2025-12-31	2026-02-26	10-K	26-000026
3	assets	us-gaap:Assets	$208.2B	2025-12-31	2026-02-26	10-K	26-000026
4	net income	us-gaap:NetIncomeLoss	$7.8B	2025-12-31	2026-02-26	10-K	26-000026
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$11.7B	2025-12-31	2026-02-26	10-K	26-000026
6	assets	us-gaap:Assets	$213.4B	2024-12-31	2026-02-26	10-K	26-000026
7	revenue	us-gaap:Revenues	$63.6B	2024-12-31	2026-02-26	10-K	26-000026
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$17.9B	2024-12-31	2026-02-26	10-K	26-000026
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$50.9B	2023-12-31	2024-02-22	10-K	24-000039
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$25.0B	2023-12-31	2026-02-26	10-K	26-000026
11	revenue	us-gaap:Revenues	$101.2B	2022-12-31	2025-02-27	10-K	25-000054
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$34.3B	2022-12-31	2025-02-27	10-K	25-000054
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$73.6B	2021-12-31	2024-02-22	10-K	24-000039
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$30.8B	2021-12-31	2024-02-22	10-K	24-000039
15	current assets	us-gaap:AssetsCurrent	$42.9B	2025-12-31	2026-02-26	10-K	26-000026
16	current liabilities	us-gaap:LiabilitiesCurrent	$37.0B	2025-12-31	2026-02-26	10-K	26-000026
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.6B	2025-12-31	2026-02-26	10-K	26-000026
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$12.7B	2024-12-31	2026-02-26	10-K	26-000026
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.9B	2024-12-31	2026-02-26	10-K	26-000026
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$8.7B	2023-12-31	2026-02-26	10-K	26-000026
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.9B	2023-12-31	2026-02-26	10-K	26-000026
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$29.3B	2022-12-31	2025-02-27	10-K	25-000054
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.2B	2022-12-31	2025-02-27	10-K	25-000054
24	assets	us-gaap:Assets	$226.5B	2023-12-31	2025-02-27	10-K	25-000054
25	assets	us-gaap:Assets	$197.2B	2022-12-31	2024-02-22	10-K	24-000039

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,686,267,431	2026-02-19	2026-02-26	10-K	26-000026
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,667,340,414	2025-02-20	2025-02-27	10-K	25-000054